EP 3934640 A1 20220112 - COMPOSITION COMPRISING MONOACETYLDIACYLGLYCEROL COMPOUND FOR TREATING FATTY LIVER DISEASE
Title (en)
COMPOSITION COMPRISING MONOACETYLDIACYLGLYCEROL COMPOUND FOR TREATING FATTY LIVER DISEASE
Title (de)
ZUSAMMENSETZUNG MIT EINER MONOACETYLDIACYLGLYCEROLVERBINDUNG ZUR BEHANDLUNG VON FETTLEBERKRANKHEIT
Title (fr)
COMPOSITION COMPRENANT UN COMPOSÉ DE MONOACÉTYLDIACYLGLYCÉROL POUR LE TRAITEMENT DE LA STÉATOSE HÉPATIQUE
Publication
Application
Priority
- KR 20190026326 A 20190307
- KR 20190086967 A 20190718
- US 201962908392 P 20190930
- IB 2020051990 W 20200306
Abstract (en)
[origin: AU2020231261A1] Disclosed is a composition for treating fatty liver disease. The composition comprises a monoacetyldiacylglycerol compound of Formula 1 as an active ingredient for treating fatty liver disease wherein R1 and R2 are independently a fatty acid residue of 14 to 22 carbon atoms.
IPC 8 full level
A61K 31/23 (2006.01); A23L 33/115 (2016.01); A61K 31/231 (2006.01); A61P 1/16 (2006.01)
CPC (source: EP)
A23L 33/115 (2016.07); A61K 31/231 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2017.12)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
AU 2020231261 A1 20210624; CN 113194940 A 20210730; EP 3934640 A1 20220112; EP 3934640 A4 20221207; JP 2022523464 A 20220425
DOCDB simple family (application)
AU 2020231261 A 20200306; CN 202080006890 A 20200306; EP 20766948 A 20200306; JP 2021541223 A 20200306